Search Results

You are looking at 61 - 70 of 182 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

David Scott Miller, Gini Fleming, and Marcus E. Randall

Oncology Group study . J Clin Oncol 1996 ; 14 : 357 – 361 . 19 Fiorica JV Brunetto VL Hanjani P . Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

Full access

Sofia D. Merajver and Kara Milliron

. 13 Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study . J Natl Cancer Inst 1998 ; 90 : 1371 – 1388 . 14 Rockhill B Spiegelman

Full access

William J. Gradishar

were updated to indicate that women who are postmenopausal at diagnosis and received an AI for 5 years “can consider an AI for an additional 5 years.” 5 This includes women who received tamoxifen for 5 years and wish to extend endocrine therapy to 10

Full access

Susan M. Domchek, Jill E. Stopfer, and Timothy R. Rebbeck

: 1358 – 1365 . 45. Narod SA Brunet JS Ghadirian P . Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group . Lancet 2000 ; 356 : 1876

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

breast-conserving surgery followed by radiation therapy, or mastectomy. 11 - 14 Tamoxifen is also considered as possible adjuvant therapy for patients with estrogen receptor-positive DCIS, both for reduction of local recurrence risk after breast

Full access

Melinda L. Telli, William J. Gradishar, and John H. Ward

tumors >0.5 cm, the NCCN Guidelines state as a category 1 recommendation that clinicians should “strongly consider the 21-gene assay.” The assay predicts the benefit of chemotherapy when added to tamoxifen as adjuvant therapy, regardless of menopausal

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

-negative, advanced breast cancer were randomly assigned to first-line treatment with ribociclib or placebo with goserelin plus either a nonsteroidal AI or tamoxifen. 31 An improvement in PFS was seen with the addition of ribociclib (median PFS, 24 vs 13

Full access

receptor's ligand by blocking estrogen production via aromatase enzymatic inhibition. Tamoxifen is a nonsteroidal triphenylethylene derivative that acts as a SERM, with antagonist properties in mammary tissue. Tamoxifen has demonstrated efficacy and a

Full access

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

the global MONALEESA-7 trial of almost 700 premenopausal or perimenopausal women rendered postmenopausal. 17 Patients had received no prior endocrine therapy for metastatic disease; by physician's choice they received an AI (mostly) or tamoxifen, plus

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

-consistent/NCCN-nonconsistent trials involved adjuvant endocrine therapy; 2 used a gonadotropin-releasing hormone (GnRH) agonist and tamoxifen in premenopausal women, and 4 used tamoxifen in postmenopausal women. A GnRH agonist with tamoxifen is included in the AGO guidelines for